Wynzora Commercialization in US Reaching Fruition

MC2 Therapeutics announces its Collaboration Agreement with EPI Health LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the United States.